Indication
Mitochondrial Pathology
2 clinical trials
3 products
1 drug
Clinical trial
A Phase 3 Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Daily Subcutaneous Injections of Elamipretide in Subjects With Primary Mitochondrial Disease Resulting From Pathogenic Nuclear DNA Mutations (nPMD) NuPowerStatus: Active (not recruiting), Estimated PCD: 2024-09-01
Product
PlaceboProduct
ElamipretideClinical trial
The Effect of Trimetazidine on Mitochondrial Function, Myocardial Performance, and Invasive Hemodynamics in Patients Diagnosed With Wild-Type Transthyretin Cardiac AmyloidosisStatus: Completed, Estimated PCD: 2023-06-01
Product
TrimetazidineDrug
Varlilumab